Cambodia and Laos Pharmaceuticals and Healthcare Report Q2 2016

71 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: Despite Cambodia’s latest move to expand health coverage for workers, we highlight that the
country’s lack of investments in healthcare means that the effective coverage of the policy will be low.
Consequently, any market potential within Cambodia will still be overshadowed by its neighbours.
Headline Expenditure Projections
? Pharmaceuticals: KHR1,008.1bn (USD252mn) in 2015 to KHR1,113.5bn (USD278mn) in 2016;
+10.5% in local currency terms and US dollar terms.
? Healthcare: KHR5,676.2bn (USD1.4bn) in 2015 to KHR6,292.5bn (USD1.6bn) in 2016; +10.9% in
local currency terms and US dollar terms.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Cambodia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Cambodia 2012-2020) 12
Healthcare Market Forecast 12
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2012-2020) 14
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2012-2020) 15
Pharmaceutical Trade Forecast 16
Table: Pharmaceutical Trade Data And Forecasts (Cambodia 2014-2020) 17
Industry Risk/Reward Index 18
Asia Pacific Risk/Reward Index 18
Cambodia Risk/Reward Index 24
Rewards 24
Risks 24
Market Overview 26
Healthcare Sector 26
Health Insurance 28
Research & Development 29
Clinical Trials 30
Epidemiology 31
Regulatory Review 34
Regulatory Regime 34
Intellectual Property Issues 34
Counterfeit Medicines 35
Pricing And Reimbursement 36
Competitive Landscape 37
Pharmaceutical Sector 37
Table: Multinational Market Activity 39
Wholesale Sector 40
Company Profile 42
Pfizer 42
PharmaProduct Manufacturing (PPM) 44
Sanofi 47
Demographic Forecast 50
Table: Population Headline Indicators (Cambodia 1990-2025) 51
Table: Key Population Ratios (Cambodia 1990-2025) 51
Table: Urban/Rural Population & Life Expectancy (Cambodia 1990-2025) 52
Table: Population By Age Group (Cambodia 1990-2025) 52
Table: Population By Age Group % (Cambodia 1990-2025) 53
Demographic Forecast 55
Table: Population Headline Indicators (Laos 1990-2025) 56
Table: Key Population Ratios (Laos 1990-2025) 56
Table: Urban/Rural Population & Life Expectancy (Laos 1990-2025) 57
Table: Population By Age Group (Laos 1990-2025) 57
Table: Population By Age Group % (Laos 1990-2025) 58
Demographic Forecast 60
Table: Population Headline Indicators (Myanmar 1990-2025) 61
Table: Key Population Ratios (Myanmar 1990-2025) 61
Table: Urban/Rural Population & Life Expectancy (Myanmar 1990-2025) 62
Table: Population By Age Group (Myanmar 1990-2025) 62
Table: Population By Age Group % (Myanmar 1990-2025) 63
Glossary 65
Methodology 67
Pharmaceutical Expenditure Forecast Model 67
Healthcare Expenditure Forecast Model 67
Notes On Methodology 68
Risk/Reward Index Methodology 69
Index Overview 70
Table: Pharmaceutical Risk/Reward Index Indicators 70
Indicator Weightings 71

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Cambodia 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Cambodia 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Cambodia 2014-2020)
Table: Multinational Market Activity
Table: Population Headline Indicators (Cambodia 1990-2025)
Table: Key Population Ratios (Cambodia 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Cambodia 1990-2025)
Table: Population By Age Group (Cambodia 1990-2025)
Table: Population By Age Group % (Cambodia 1990-2025)
Table: Population Headline Indicators (Laos 1990-2025)
Table: Key Population Ratios (Laos 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Laos 1990-2025)
Table: Population By Age Group (Laos 1990-2025)
Table: Population By Age Group % (Laos 1990-2025)
Table: Population Headline Indicators (Myanmar 1990-2025)
Table: Key Population Ratios (Myanmar 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Myanmar 1990-2025)
Table: Population By Age Group (Myanmar 1990-2025)
Table: Population By Age Group % (Myanmar 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Cambodia and Laos Pharmaceuticals and Healthcare Report Q1 2016BMI View: While the underdeveloped nature of its pharmaceutical and health care sector will bring about commercial benefits for foreign investors, competition from relatively low risk and higher rewards markets such as Vietnam means that Cambodia will remain low on investors'' priority list. Headline Expenditure Projections ? Pharmaceuticals: KHR910.8bn (USD228mn) in 2014 to KHR1,008.1bn (USD252mn) in 2015; +10.7% in local currency terms and US dollar terms. Forecast remains […]
  • Cambodia and Laos Pharmaceuticals and Healthcare Report Q4 2014BMI View: The current lack of investment in healthcare in Cambodia will continue to deter foreign pharmaceutical firms from entering the country. Consequently, we highlight that Cambodia will remain one of the least attractive markets in South East Asia. Headline Expenditure Projections ? Pharmaceuticals: KHR821.7bn (USD204mn) in 2013 to KHR908.9bn (USD227mn) in 2014; +10.6% in local currency terms and +11.2% in US dollar terms. Forecast slightly downgraded from previous quarter. ? […]
  • Cambodia and Laos Pharmaceuticals and Healthcare Report Q3 2015BMI View: Despite improvements to the healthcare sector, high out of pocket expenditure means that access to healthcare will remain a challenging issue in Cambodia. Further investments in the sector will boost overall care quality and boost investments into the pharmaceutical sector. Headline Expenditure Projections ? Pharmaceuticals: KHR910.8bn (USD228mn) in 2014 to KHR10007.2bn (USD252mn) in 2015; +10.6% in local currency terms and US dollar terms. Forecast remains unchanged from […]
  • Cambodia and Laos Pharmaceuticals and Healthcare Report Q4 2015BMI View: Commercial opportunities for drugmakers in Cambodia will remain limited despite the rising burden of both communicable and non-communicable diseases. Critically, the country's healthcare system remains underdeveloped, hindering access to pharmaceuticals and medical diagnosis. Moreover, revenue prospects for high value medicines remain limited due to the low purchasing power of the population and the dominance of out-of-pocket spending in healthcare financing. Headline […]
  • Cambodia and Laos Pharmaceuticals and Healthcare Report Q1 2015BMI View: Access to healthcare and financial sustainability are two key challenges that will weigh on the effectiveness of Cambodia's universal healthcare programme. Expected to be implemented by 2025, the scheme will provide revenue earning opportunities to pharmaceutical firms with generic drug portfolios. Headline Expenditure Projections ? Pharmaceuticals: KHR821.7bn (USD204mn) in 2013 to KHR910.8bn (USD228mn) in 2014; +10.8% in local currency terms and +11.4% in US dollar terms. […]